{"result": "(\"entity\"<|>CLINICAL NUTRITION<|>ORGANIZATION<|>Clinical Nutrition is a journal that publishes research related to nutrition and its effects on health, including studies on pancreatitis.)\n##\n(\"entity\"<|>LANCET<|>ORGANIZATION<|>The Lancet is a prestigious medical journal that publishes research and reviews on various medical topics, including clinical trials related to pancreatitis.)\n##\n(\"entity\"<|>GASTROENTEROLOGY<|>ORGANIZATION<|>Gastroenterology is a leading journal in the field of digestive diseases, publishing studies and reviews on conditions like chronic pancreatitis.)\n##\n(\"entity\"<|>AMERICAN JOURNAL OF GASTROENTEROLOGY<|>ORGANIZATION<|>The American Journal of Gastroenterology publishes research and reviews on gastrointestinal diseases, including pancreatitis.)\n##\n(\"entity\"<|>PANCREATOLOGY<|>ORGANIZATION<|>Pancreatology is a journal focused on the study and treatment of pancreatic diseases, including chronic pancreatitis.)\n##\n(\"entity\"<|>CHRONIC PANCREATITIS<|>EVENT<|>Chronic pancreatitis is a long-term inflammatory condition of the pancreas that can lead to pain and digestive issues, often requiring medical management.)\n##\n(\"entity\"<|>PROBIOTICS<|>EVENT<|>Probiotics are live microorganisms that may provide health benefits, and their use is being studied in critically ill patients, including those with pancreatitis.)\n##\n(\"entity\"<|>NUTRITIONAL MANAGEMENT<|>EVENT<|>Nutritional management refers to dietary strategies and interventions aimed at improving health outcomes in patients with pancreatic diseases.)\n##\n(\"relationship\"<|>CLINICAL NUTRITION<|>LANCET<|>Both journals publish research related to nutrition and its impact on health, including studies on pancreatitis<|>5)\n##\n(\"relationship\"<|>GASTROENTEROLOGY<|>AMERICAN JOURNAL OF GASTROENTEROLOGY<|>Both journals focus on gastrointestinal diseases and publish research on conditions like chronic pancreatitis<|>5)\n##\n(\"relationship\"<|>PANCREATOLOGY<|>CHRONIC PANCREATITIS<|>Pancreatology is a journal that publishes studies specifically related to chronic pancreatitis<|>7)\n##\n(\"relationship\"<|>PROBIOTICS<|>CHRONIC PANCREATITIS<|>Probiotics are being studied for their potential benefits in managing chronic pancreatitis<|>4)\n##\n(\"relationship\"<|>NUTRITIONAL MANAGEMENT<|>CHRONIC PANCREATITIS<|>Nutritional management is crucial for patients with chronic pancreatitis to alleviate symptoms and improve quality of life<|>6)\n<|COMPLETE|>", "input": "\n-Goal-\nGiven a text document that is potentially relevant to this activity and a list of entity types, identify all entities of those types from the text and all relationships among the identified entities.\n \n-Steps-\n1. Identify all entities. For each identified entity, extract the following information:\n- entity_name: Name of the entity, capitalized\n- entity_type: One of the following types: [organization,person,geo,event]\n- entity_description: Comprehensive description of the entity's attributes and activities\nFormat each entity as (\"entity\"<|><entity_name><|><entity_type><|><entity_description>)\n \n2. From the entities identified in step 1, identify all pairs of (source_entity, target_entity) that are *clearly related* to each other.\nFor each pair of related entities, extract the following information:\n- source_entity: name of the source entity, as identified in step 1\n- target_entity: name of the target entity, as identified in step 1\n- relationship_description: explanation as to why you think the source entity and the target entity are related to each other\n- relationship_strength: a numeric score indicating strength of the relationship between the source entity and target entity\n Format each relationship as (\"relationship\"<|><source_entity><|><target_entity><|><relationship_description><|><relationship_strength>)\n \n3. Return output in English as a single list of all the entities and relationships identified in steps 1 and 2. Use **##** as the list delimiter.\n \n4. When finished, output <|COMPLETE|>\n \n######################\n-Examples-\n######################\nExample 1:\nEntity_types: ORGANIZATION,PERSON\nText:\nThe Verdantis's Central Institution is scheduled to meet on Monday and Thursday, with the institution planning to release its latest policy decision on Thursday at 1:30 p.m. PDT, followed by a press conference where Central Institution Chair Martin Smith will take questions. Investors expect the Market Strategy Committee to hold its benchmark interest rate steady in a range of 3.5%-3.75%.\n######################\nOutput:\n(\"entity\"<|>CENTRAL INSTITUTION<|>ORGANIZATION<|>The Central Institution is the Federal Reserve of Verdantis, which is setting interest rates on Monday and Thursday)\n##\n(\"entity\"<|>MARTIN SMITH<|>PERSON<|>Martin Smith is the chair of the Central Institution)\n##\n(\"entity\"<|>MARKET STRATEGY COMMITTEE<|>ORGANIZATION<|>The Central Institution committee makes key decisions about interest rates and the growth of Verdantis's money supply)\n##\n(\"relationship\"<|>MARTIN SMITH<|>CENTRAL INSTITUTION<|>Martin Smith is the Chair of the Central Institution and will answer questions at a press conference<|>9)\n<|COMPLETE|>\n\n######################\nExample 2:\nEntity_types: ORGANIZATION\nText:\nTechGlobal's (TG) stock skyrocketed in its opening day on the Global Exchange Thursday. But IPO experts warn that the semiconductor corporation's debut on the public markets isn't indicative of how other newly listed companies may perform.\n\nTechGlobal, a formerly public company, was taken private by Vision Holdings in 2014. The well-established chip designer says it powers 85% of premium smartphones.\n######################\nOutput:\n(\"entity\"<|>TECHGLOBAL<|>ORGANIZATION<|>TechGlobal is a stock now listed on the Global Exchange which powers 85% of premium smartphones)\n##\n(\"entity\"<|>VISION HOLDINGS<|>ORGANIZATION<|>Vision Holdings is a firm that previously owned TechGlobal)\n##\n(\"relationship\"<|>TECHGLOBAL<|>VISION HOLDINGS<|>Vision Holdings formerly owned TechGlobal from 2014 until present<|>5)\n<|COMPLETE|>\n\n######################\nExample 3:\nEntity_types: ORGANIZATION,GEO,PERSON\nText:\nFive Aurelians jailed for 8 years in Firuzabad and widely regarded as hostages are on their way home to Aurelia.\n\nThe swap orchestrated by Quintara was finalized when $8bn of Firuzi funds were transferred to financial institutions in Krohaara, the capital of Quintara.\n\nThe exchange initiated in Firuzabad's capital, Tiruzia, led to the four men and one woman, who are also Firuzi nationals, boarding a chartered flight to Krohaara.\n\nThey were welcomed by senior Aurelian officials and are now on their way to Aurelia's capital, Cashion.\n\nThe Aurelians include 39-year-old businessman Samuel Namara, who has been held in Tiruzia's Alhamia Prison, as well as journalist Durke Bataglani, 59, and environmentalist Meggie Tazbah, 53, who also holds Bratinas nationality.\n######################\nOutput:\n(\"entity\"<|>FIRUZABAD<|>GEO<|>Firuzabad held Aurelians as hostages)\n##\n(\"entity\"<|>AURELIA<|>GEO<|>Country seeking to release hostages)\n##\n(\"entity\"<|>QUINTARA<|>GEO<|>Country that negotiated a swap of money in exchange for hostages)\n##\n##\n(\"entity\"<|>TIRUZIA<|>GEO<|>Capital of Firuzabad where the Aurelians were being held)\n##\n(\"entity\"<|>KROHAARA<|>GEO<|>Capital city in Quintara)\n##\n(\"entity\"<|>CASHION<|>GEO<|>Capital city in Aurelia)\n##\n(\"entity\"<|>SAMUEL NAMARA<|>PERSON<|>Aurelian who spent time in Tiruzia's Alhamia Prison)\n##\n(\"entity\"<|>ALHAMIA PRISON<|>GEO<|>Prison in Tiruzia)\n##\n(\"entity\"<|>DURKE BATAGLANI<|>PERSON<|>Aurelian journalist who was held hostage)\n##\n(\"entity\"<|>MEGGIE TAZBAH<|>PERSON<|>Bratinas national and environmentalist who was held hostage)\n##\n(\"relationship\"<|>FIRUZABAD<|>AURELIA<|>Firuzabad negotiated a hostage exchange with Aurelia<|>2)\n##\n(\"relationship\"<|>QUINTARA<|>AURELIA<|>Quintara brokered the hostage exchange between Firuzabad and Aurelia<|>2)\n##\n(\"relationship\"<|>QUINTARA<|>FIRUZABAD<|>Quintara brokered the hostage exchange between Firuzabad and Aurelia<|>2)\n##\n(\"relationship\"<|>SAMUEL NAMARA<|>ALHAMIA PRISON<|>Samuel Namara was a prisoner at Alhamia prison<|>8)\n##\n(\"relationship\"<|>SAMUEL NAMARA<|>MEGGIE TAZBAH<|>Samuel Namara and Meggie Tazbah were exchanged in the same hostage release<|>2)\n##\n(\"relationship\"<|>SAMUEL NAMARA<|>DURKE BATAGLANI<|>Samuel Namara and Durke Bataglani were exchanged in the same hostage release<|>2)\n##\n(\"relationship\"<|>MEGGIE TAZBAH<|>DURKE BATAGLANI<|>Meggie Tazbah and Durke Bataglani were exchanged in the same hostage release<|>2)\n##\n(\"relationship\"<|>SAMUEL NAMARA<|>FIRUZABAD<|>Samuel Namara was a hostage in Firuzabad<|>2)\n##\n(\"relationship\"<|>MEGGIE TAZBAH<|>FIRUZABAD<|>Meggie Tazbah was a hostage in Firuzabad<|>2)\n##\n(\"relationship\"<|>DURKE BATAGLANI<|>FIRUZABAD<|>Durke Bataglani was a hostage in Firuzabad<|>2)\n<|COMPLETE|>\n\n######################\n-Real Data-\n######################\nEntity_types: organization,person,geo,event\nText: völ-\n    gyi T, Desci T et al. Effect on enterally administered\n    n-3 polyinsatured fatty acids in acute pancreati-\n    tis–a prospective randomized clinical trial. Clin\n    Nutr 2005; 24: 198-205.\n49. McNaught CE, Woodcock NP, Anderson ADG, Mc-\n    Fie J. A prospective randomised tial of probiotics in\n    critically ill patients. Clin Nutr 2005;24: 211-19.\n50. Besselink MG, Van Santvoort HC, BuskensE, Boer-\n    meester Ma, Van Goor H, Timmerman HM et al.\n    Probiotic prophylaxis in predicted severe acute\n\npancreatitis: a randomised, double-blind, placebo\ncontrolled trial. Lancet 2008; 371: 651-59.\n51. Bi Y, Atwal T, Vege SS. Drug Therapy for Acute\n    Pancreatitis. Curr Treat Options Gastroenterol.\n    2015 Sep;13(3):354-68.\n52. Poropat G, Giljaca V, Hauser G, Štimac D. Enteral nu-\n    trition formulations for acute pancreatitis. Cochrane\n    Database Syst Rev. 2015 Mar 23;(3) CD010605. doi:\n    10.1002/14651858.CD010605.pub2.\n53. Foitzik T, Eibl G, Schneider P et al. ω-3 fatty acid\n    supplementation increases anti-inflamatory cyto-\n    kines and attenuates systemic disease sequelae in\n    experimental pancreatitis. JPEN 2002; 26(6):\n    351-56.\n54. Mayer K, Meyer S, Reinholz-Muhly M, Maus U,\n    MerfelsM, Lohmeyer J eta l. Short-time infusion of\n    fish oil-based lipid emulsions, approved for paren-\n    teral nutrition, reduces monocyte proinflam-\n    matory cytokine generation and adhesive interac-\n    tion with endothelium in humans. J immunol\n    2003; 17(9): 4837-43.\n55. Ammann RW, Heitz PU, Kloepple G. Course of al-\n    coholic chronic pancreatitis: A prospective clinico-\n    morphological long term study. Gastroenterology\n    1996; 11: 224-31.\n56. Steer ML, Waxman I, Freedman S. Chronic Pan-\n    creatitis. N Engl J Med 1995; 332: 1482.\n57. Buscail L. Diagnosis and Management of Chronic\n    Pancreatitis. Rev Prat 2002; 15 52 (14): 1561-66.\n58. Singh VV, Toskes PP. Medical Therapy for chronic\n    pancreatitis pain. Curr Gastroenterol Rep2003;5:110.\n59. Ockenga J. Importance of nutritional manage-\n    ment in diseases with exocrine pancreatic insuffi-\n    ciency. HPB (Oxford). 2009 Dec;11 Suppl 3:11-15.\n60. Shea JC, Bishop MD, Parker EM, Gelrud A, Freed-\n    men Sd. An enteral therapy containing me-\n    dium-chain triglycerides and hydrolized peptides\n    reduces postprandial pain associated with chronic\n    pancreatitis. Pancreatology 2003; 3(1): 36-40.\n61. Ihse I, Andersson R, Albiin N, Borgstrom A, Daniel-\n    son A, Hammarstrom LE et al. Guidelines for ma-\n    nagement of patients with chronic pancreatitis.\n    Report from consensus conference. Lakartidnin-\n    gen 2003; 100 (32-33): 2518-25.\n62. Hoffmeister A et L. English language version of the\n    S3-consensus guidelines on chronic pancreatitis:\n    Definition, aetiology, diagnostic examinations,\n    medical, endocopic and surgical management of\n    chronic pancreatitis. Z Gastroenterol. 2015\n    Dec;53(12):1447-95.\n63. Larvin M, MCMahon MJ, Thomas WEG et al. Creon\n    (enteric coated pancreatic microspheres) for the\n    treatment of pain in chronic pancreatitis: a dou-\n    ble-blind randomized placebo-controlled crossover\n    trial (abstract). Gastroenterology 1991; 100: A283.\n64. Brown A, Hughes M, Tenner S, Banks Pa. Does\n    pancreatic enzyme supplementation reduce\n---\nTema 29. Soporte nutricional en enfermedades pancreáticas   479\n\npain in patients with chronic pancreatitis?: a meta-analysis. Am J Gastroenterol 1997; 92: 2032-35.\n\n65. Trolli PA, Conwell DL, Zuccaro G Jr. Pancreatic enzyme therapy and nutricional status of patients with chronic pancreatitis. Gastroenterol Nurs 2001; 24 (2): 84-87.\n\n66. Shea JC, Hopper IK, Blanco PG, Freedman SD. Advances in nutricional management of chronic pancreatits. Curr Gastroenterol Rep 2000; 2(4): 323-26.\n\n67. Uden S, Bildon D, Nathan L et al. Antioxidant therapy for current\n######################\nOutput:", "parameters": {"model": "gpt-4o-mini", "temperature": 0.0, "frequency_penalty": 0.0, "presence_penalty": 0.0, "top_p": 1.0, "max_tokens": 4000, "n": 1}, "history": null}